Enable Biosciences

Enable Biosciences is a private, commercial-stage diagnostics company developing advanced antibody detection tests for predictive medicine. Its core technology, ADAP, enables highly accurate screening for autoantibodies associated with type 1 diabetes, allowing for early risk assessment years before clinical onset. The company has validated its platform through significant partnerships and government grants, is actively commercializing its T1D test, and is exploring applications in other autoimmune conditions. Its business model is centered on providing diagnostic testing services and kits to healthcare providers and researchers.

Antibody Detection by Aggregation PCR (ADAP) - a highly sensitive and multiplexed platform using DNA-barcoded reagents and PCR amplification to detect disease-specific antibodies from small sample volumes.

Enable competes in the autoimmune diagnostics space with large commercial labs (Quest, LabCorp) offering traditional autoantibody tests and specialized companies like Roche, Siemens Healthineers, and Thermo Fisher. Its competitive edge lies in the superior sensitivity, multiplexing capability, and potential cost-effectiveness of its patented ADAP technology, which is designed specifically for scalable, population-level screening.